SK286024B6 - Farmaceutický prostriedok a použitie tohto prostriedku na prípravu liečiva - Google Patents

Farmaceutický prostriedok a použitie tohto prostriedku na prípravu liečiva Download PDF

Info

Publication number
SK286024B6
SK286024B6 SK673-99A SK67399A SK286024B6 SK 286024 B6 SK286024 B6 SK 286024B6 SK 67399 A SK67399 A SK 67399A SK 286024 B6 SK286024 B6 SK 286024B6
Authority
SK
Slovakia
Prior art keywords
platelet
heparin
compound
enoxaparin
pharmaceutical composition
Prior art date
Application number
SK673-99A
Other languages
English (en)
Slovak (sk)
Other versions
SK67399A3 (en
Inventor
Andre Uzan
Alain Curaudeau
Robert J. Leadley
Christopher T. Dunwiddie
Mark H. Perrone
Original Assignee
Aventis Pharmaceuticals Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=21861879&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SK286024(B6) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Aventis Pharmaceuticals Inc. filed Critical Aventis Pharmaceuticals Inc.
Publication of SK67399A3 publication Critical patent/SK67399A3/sk
Publication of SK286024B6 publication Critical patent/SK286024B6/sk

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/05—Dipeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Molecular Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SK673-99A 1996-11-27 1997-11-24 Farmaceutický prostriedok a použitie tohto prostriedku na prípravu liečiva SK286024B6 (sk)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US3187896P 1996-11-27 1996-11-27
PCT/US1997/021440 WO1998023279A1 (en) 1996-11-27 1997-11-24 PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND

Publications (2)

Publication Number Publication Date
SK67399A3 SK67399A3 (en) 2000-07-11
SK286024B6 true SK286024B6 (sk) 2008-01-07

Family

ID=21861879

Family Applications (1)

Application Number Title Priority Date Filing Date
SK673-99A SK286024B6 (sk) 1996-11-27 1997-11-24 Farmaceutický prostriedok a použitie tohto prostriedku na prípravu liečiva

Country Status (28)

Country Link
US (2) US6103705A (ja)
EP (1) EP0946185B2 (ja)
JP (1) JP4498471B2 (ja)
KR (1) KR100512671B1 (ja)
CN (1) CN1121224C (ja)
AP (1) AP1390A (ja)
AT (1) ATE283062T1 (ja)
AU (1) AU754936B2 (ja)
BG (1) BG64542B1 (ja)
BR (1) BR9713141A (ja)
CA (1) CA2272317C (ja)
CZ (1) CZ298552B6 (ja)
DE (1) DE69731763T3 (ja)
DK (1) DK0946185T4 (ja)
EA (1) EA002475B1 (ja)
ES (1) ES2230624T5 (ja)
HK (1) HK1023504A1 (ja)
HU (1) HUP9903496A3 (ja)
IL (1) IL129877A (ja)
NO (1) NO327740B1 (ja)
OA (1) OA11049A (ja)
PL (1) PL189116B1 (ja)
PT (1) PT946185E (ja)
SI (1) SI0946185T2 (ja)
SK (1) SK286024B6 (ja)
UA (1) UA63929C2 (ja)
WO (1) WO1998023279A1 (ja)
ZA (1) ZA9710691B (ja)

Families Citing this family (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754936B2 (en) * 1996-11-27 2002-11-28 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound
FR2764511B1 (fr) 1997-06-13 2000-09-08 Sanofi Sa Compositions pour le traitement et la prevention de la thrombose arterielle et utilisation d'un inhibiteur du facteur xa seul et/ou en combinaison avec un antiagregant plaquettaire
US6136794A (en) * 1998-02-02 2000-10-24 Merck & Co., Inc. Platelet aggregation inhibition using low molecular weight heparin in combination with a GP IIb/IIIa antagonist
AU1712700A (en) * 1998-11-18 2000-06-05 G.D. Searle & Co. Restoration of platelet aggregation by antibody administration after gpiib/iiia antagonist treatment
CA2377734A1 (en) * 1999-06-30 2001-01-11 Hamilton Civic Hospitals Research Development, Inc. Heparin compositions that inhibit clot associated coagulation factors
ES2161615B1 (es) * 1999-07-23 2003-03-16 Rovi Lab Farmaceut Sa Composiciones de heparinas de muy bajo peso molecular.
US6969705B2 (en) * 2000-07-21 2005-11-29 Aventis Pharma S.A. Compositions of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
JP2004507562A (ja) * 2000-09-08 2004-03-11 ハミルトン　シビック　ホスピタルズ　リサーチ　ディベロップメント　インコーポレイテッド 抗血栓性組成物
US6982251B2 (en) * 2000-12-20 2006-01-03 Schering Corporation Substituted 2-azetidinones useful as hypocholesterolemic agents
DE10141106A1 (de) * 2001-08-22 2003-03-13 Aventis Pharma Gmbh Verwendung von Heparinoid-Derivaten zur Behandlung und Diagnose von mit Heparinoiden behandelbaren Erkrankungen
US20040171819A1 (en) * 2002-10-10 2004-09-02 Aventis Pharma S.A. Mixtures of polysaccharides derived from heparin, their preparation and pharmaceutical compositions containing them
ATE418551T1 (de) 2003-03-07 2009-01-15 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
DE602004016123D1 (de) * 2003-03-07 2008-10-09 Schering Corp Substituierte azetidinon-derivate, deren pharmazeutische formulierungen und deren verwendung zur behandlung von hypercholesterolemia
US7956046B2 (en) * 2003-07-24 2011-06-07 Aventis Pharma S.A. Oligosaccharide mixtures derived from heparin, preparation thereof and pharmaceutical compositions containing them
EP1537871A1 (en) * 2003-12-04 2005-06-08 Aventis Pharma S.A. Enoxaparin for the treatment of cancer
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
KR100601429B1 (ko) * 2004-07-09 2006-07-14 주식회사 대우일렉트로닉스 기계식 전자렌지의 댐퍼 구동회로
EP2014296A1 (en) * 2007-07-10 2009-01-14 PAION Deutschland GmbH Novel strategies for increasing the reperfusion in obstructed blood vessel
AR067345A1 (es) * 2007-07-10 2009-10-07 Paion Deutschland Gmbh Uso de trombomodulina para la preparacion de un medicamento trombolitico
CN101783857B (zh) * 2009-05-12 2011-11-30 上海海事大学 一种基于fpga在高分辨率成像系统中的图像矩阵化预处理方法
IT1400232B1 (it) * 2010-05-07 2013-05-24 Advance Holdings Ltd Composizione farmaceutica topica comprendente eparina
WO2011149110A1 (en) 2010-05-28 2011-12-01 Daiichi Sankyo Company, Limited Novel composition for the prevention and/or treatment of thromboembolism
EP2508892A1 (de) * 2011-04-04 2012-10-10 Siemens Healthcare Diagnostics Products GmbH Kontrollen und Kit für Thrombozytenaktivitätsteste
RU2554803C1 (ru) * 2014-06-26 2015-06-27 Федеральное государственное бюджетное учреждение "Ростовский научно-исследовательский онкологический институт" Министерства здравоохранения Российской Федерации Способ профилактики развития послеоперационных венозных тромбоэмболических осложнений у пациентов с колоректальным раком

Family Cites Families (45)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3766167A (en) * 1971-03-26 1973-10-16 Research Corp Orally active anticoagulant
SE449753B (sv) * 1978-11-06 1987-05-18 Choay Sa Mukopolysackaridkomposition med reglerande verkan pa koagulation, lekemedel innehallande densamma samt forfarande for framstellning derav
FR2440376A1 (fr) * 1978-11-06 1980-05-30 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
US4692435A (en) * 1978-11-06 1987-09-08 Choay, S.A. Mucopolysaccharide composition having a regulatory action on coagulation, medicament containing same and process of preparation
FR2478646A2 (fr) * 1980-03-20 1981-09-25 Choay Sa Composition mucopolysaccharidique ayant une activite regulatrice de la coagulation, medicament la contenant et procede pour l'obtenir
CA1136620A (en) * 1979-01-08 1982-11-30 Ulf P.F. Lindahl Heparin fragments having selective anticoagulation activity
US4826827A (en) * 1979-10-05 1989-05-02 Choay S.A. Short chained oligosaccharides having biological properties, a process for making the same and the use thereof as drugs
FR2482611B1 (fr) * 1980-05-14 1986-03-07 Pharmindustrie Nouveaux polysaccharides sulfates, procedes pour leur preparation et leur utilisation comme medicaments
US4351938A (en) * 1980-05-19 1982-09-28 Riker Laboratories, Inc. Anticoagulant substance
FR2503714B1 (fr) * 1981-04-10 1986-11-21 Choay Sa Procede d'obtention de mucopolysaccharides biologiquement actifs, de purete elevee, par depolymerisation de l'heparine
EP0066908B1 (en) * 1981-05-21 1985-08-28 Akzo N.V. New anti-thromboticum based on polysacharides, method for its preparation and pharmaceutical compositions
US4533549A (en) * 1983-01-04 1985-08-06 Lasker Sigmund E Antithrombotic agent
IT1195497B (it) * 1983-03-08 1988-10-19 Opocrin Spa Procedimento per la preparazione di frazioni oligosaccaridiche dotate di proprieta' farmacologiche per degradazione chimica di eparina
US4683291A (en) * 1985-10-28 1987-07-28 Scripps Clinic And Research Foundation Platelet binding inhibitors
DK196886D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
DK196986D0 (da) * 1986-04-30 1986-04-30 Novo Industri As Fremstilling af polysaccharider
US4833155A (en) * 1986-11-25 1989-05-23 Syntex (U.S.A.) Inc. 3-(ω-(3,5,-di-t-butyl-4-hydroxyphenyl)-alkanoyl)pyrroles, and anti-inflammatory uses thereof
EP0275748B1 (fr) * 1986-12-15 1992-08-19 Institut National De La Sante Et De La Recherche Medicale (Inserm) Nouveaux dérivés peptidiques et leur application notamment en thérapeutique
US4857508A (en) * 1987-12-03 1989-08-15 Monsanto Company Novel platelet-aggregation inhibitor peptide derivatives
KR940009084B1 (ko) * 1988-05-18 1994-09-29 체크 포인트 시스템스, 인코오퍼레이티드 자기 및 공명회로 검출용 안테나 시스템
IT1234508B (it) * 1988-06-10 1992-05-19 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5037808A (en) * 1988-07-20 1991-08-06 Monsanto Co. Indolyl platelet-aggregation inhibitors
US4879313A (en) * 1988-07-20 1989-11-07 Mosanto Company Novel platelet-aggregation inhibitors
US4992463A (en) * 1988-07-20 1991-02-12 Monsanto Company Thienyl peptide mimetic compounds which are useful in inhibiting platelet aggregation
IT1234826B (it) * 1989-01-30 1992-05-29 Alfa Wassermann Spa Derivati eparinici e procedimento per la loro preparazione
US5023233A (en) * 1989-07-28 1991-06-11 Merck & Co., Inc. Fibrinogen receptor antagonists
US4952562A (en) * 1989-09-29 1990-08-28 Rorer Pharmaceutical Corporation Anti-thrombotic peptides and pseudopeptides
JPH05500954A (ja) * 1989-09-29 1993-02-25 ローヌ―プーラン　ローラー　インターナショナル（ホウルディングス）　インコーポレイテッド 抗血栓性ペプチド及び疑似ペプチド
US5051405A (en) * 1989-10-10 1991-09-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptides and pseudopeptides
US5053392A (en) * 1989-12-01 1991-10-01 Rhone-Poulenc Rorer Pharmaceuticals Inc. Novel arginine, glycine, aspartic acid derivatives as platelet-aggregation inhibitors
US5086069A (en) * 1990-02-05 1992-02-04 Rorer Pharmaceutical Corporation Anti-thrombotic peptide and pseudopeptide derivatives
US5064814A (en) * 1990-04-05 1991-11-12 Rhone-Poulenc Rorer Pharmaceuticals Inc. Anti-thrombotic peptide and pseudopeptide derivatives
IL99539A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
NZ239846A (en) * 1990-09-27 1994-11-25 Merck & Co Inc Sulphonamide derivatives and pharmaceutical compositions thereof
IL99538A0 (en) * 1990-09-27 1992-08-18 Merck & Co Inc Fibrinogen receptor antagonists and pharmaceutical compositions containing them
WO1992013117A1 (en) * 1991-01-24 1992-08-06 Aerojet-General Corporation Electrochemical desensitization process
AU668865B2 (en) * 1991-05-02 1996-05-23 Irun R. Cohen Compositions for the prevention and/or treatment of pathological processes
WO1993008845A1 (en) * 1991-11-08 1993-05-13 Massachusetts Institute Of Technology Localized oligonucleotide therapy
CA2159070A1 (en) * 1993-03-29 1994-10-13 William Frank Degrado Cyclic compounds useful as inhibitors of platelet glycoprotein iib/iiia
CZ291378B6 (cs) * 1993-10-15 2003-02-12 Aventis Pharmaceuticals Inc. Pseudopeptidové sloučeniny jako antitrombotické látky, farmaceutické prostředky obsahující tyto sloučeniny a meziprodukty
US5639469A (en) * 1994-06-15 1997-06-17 Minnesota Mining And Manufacturing Company Transmucosal delivery system
US5763427A (en) * 1995-03-31 1998-06-09 Hamilton Civic Hospitals Research Development Inc. Compositions and methods for inhibiting thrombogenesis
US5721214A (en) * 1995-06-07 1998-02-24 Cor Therapeutics, Inc. Inhibitors of factor Xa
WO1997035592A1 (en) * 1996-03-28 1997-10-02 G.D. Searle & Co. Iib/iiia antagonists co-administered with aspirin and/or heparin
AU754936B2 (en) * 1996-11-27 2002-11-28 Aventis Pharmaceuticals Inc. Pharmaceutical composition comprising a compound having anti-Xa activity and a platelet aggregation antagonist compound

Also Published As

Publication number Publication date
CZ174299A3 (cs) 1999-09-15
US6103705A (en) 2000-08-15
EP0946185B1 (en) 2004-11-24
NO327740B1 (no) 2009-09-14
NO992555D0 (no) 1999-05-27
CN1121224C (zh) 2003-09-17
DK0946185T3 (da) 2005-03-21
NO992555L (no) 1999-05-27
EP0946185A1 (en) 1999-10-06
DE69731763D1 (de) 2004-12-30
SK67399A3 (en) 2000-07-11
EP0946185A4 (en) 2001-06-27
ATE283062T1 (de) 2004-12-15
AP9901517A0 (en) 1999-06-30
ES2230624T5 (es) 2010-10-25
HUP9903496A3 (en) 2001-03-28
PL189116B1 (pl) 2005-06-30
ES2230624T3 (es) 2005-05-01
SI0946185T1 (en) 2005-06-30
AU754936B2 (en) 2002-11-28
ZA9710691B (en) 1998-06-12
BG64542B1 (bg) 2005-07-29
JP4498471B2 (ja) 2010-07-07
KR100512671B1 (ko) 2005-09-07
DK0946185T4 (da) 2010-08-30
US20020032214A1 (en) 2002-03-14
AU5454698A (en) 1998-06-22
EA199900499A1 (ru) 2000-04-24
EA002475B1 (ru) 2002-06-27
DE69731763T3 (de) 2010-12-30
UA63929C2 (uk) 2004-02-16
SI0946185T2 (sl) 2010-08-31
IL129877A (en) 2004-08-31
BR9713141A (pt) 2000-02-08
PT946185E (pt) 2005-02-28
CZ298552B6 (cs) 2007-10-31
KR20000057265A (ko) 2000-09-15
EP0946185B2 (en) 2010-05-05
WO1998023279A1 (en) 1998-06-04
JP2001506603A (ja) 2001-05-22
HUP9903496A2 (hu) 2000-10-28
OA11049A (en) 2002-02-18
AP1390A (en) 2005-04-15
HK1023504A1 (en) 2000-09-15
CN1238693A (zh) 1999-12-15
DE69731763T2 (de) 2005-06-30
IL129877A0 (en) 2000-02-29
BG103372A (en) 2000-01-31
CA2272317C (en) 2001-01-30

Similar Documents

Publication Publication Date Title
SK286024B6 (sk) Farmaceutický prostriedok a použitie tohto prostriedku na prípravu liečiva
US20220313739A1 (en) Platelet rich plasma formulations and use thereof
Hanke et al. Inhibition of cellular proliferation after experimental balloon angioplasty by low-molecular-weight heparin.
Mombelli et al. Effect of heparin on plasma fibrinopeptide A in patients with acute myocardial infarction.
Sniecinski et al. Anticoagulation management associated with extracorporeal circulation
WO2009061697A1 (en) Anticoagulant antagonist and hemophilia procoagulant
JP2003526617A (ja) 種々の血栓塞栓性障害の予防および治療のための併用療法を提供する低分子量へパリンと血小板凝集阻害剤との相乗効果
WO2011038047A1 (en) Methods of treatment with a low molecular weight heparin composition
Buchanan et al. Prevention of thrombus formation and growth by antithrombin III and heparin cofactor II-dependent thrombin inhibitors: importance of heparin cofactor II
Mickelson et al. High dose intravenous aspirin, not low dose intravenous or oral aspirin, inhibits thrombus formation and stabilizes blood flow in experimental coronary vascular injury
JP3838680B2 (ja) 抗凝血物質に対する解毒剤として用いるのに適した医薬およびその使用
Freudenberger et al. Antithrombotic effect of FK506 vs cyclosporine in cardiac transplant recipients: potential implications in transplant arteriopathy
MXPA99005008A (en) PHARMACEUTICAL COMPOSITION COMPRISING A COMPOUND HAVING ANTI-Xa ACTIVITY AND A PLATELET AGGREGATION ANTAGONIST COMPOUND
Arnljots et al. Antithrombotic and platelet activating effects of heparin in prevention of microarterial thrombosis
JP2004507562A (ja) 抗血栓性組成物
JP2005532306A (ja) 血小板凝集を阻害する方法
Cella et al. Heparin neutralizing activity (HNA) and antithrombin III in coronary artery disease
Christiansen et al. Coronary artery bypass grafting in a patient with type II heparin associated thrombopenia
Krupiński The effect of buflomedil upon the parameters of vascular flow and blood rheology in patients with obliterative atherosclerosis of lower extremities

Legal Events

Date Code Title Description
MM4A Patent lapsed due to non-payment of maintenance fees

Effective date: 20121124